Welcome to our dedicated page for Theseus Pharmaceuticals news (Ticker: THRX), a resource for investors and traders seeking the latest updates and insights on Theseus Pharmaceuticals stock.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) is a clinical-stage biopharmaceutical leader developing pan-variant kinase inhibitors to combat cancer treatment resistance. This page provides investors and researchers with essential updates on the company's clinical programs, strategic partnerships, and corporate developments.
Access comprehensive coverage of THRX announcements including trial progress for fourth-generation EGFR inhibitor THE-349, pipeline candidate nominations, and analysis of the Concentra Biosciences merger. Our curated news collection eliminates the need to track multiple sources for material updates affecting shareholder value.
Key content areas include: clinical trial milestones, financial performance updates, research collaborations, and regulatory filings. Stay informed about developments in NSCLC, CML, and GIST therapies while monitoring the company's extended cash runway through 2026.
Bookmark this page for real-time updates on Theseus' innovative approach to overcoming cancer resistance mechanisms. Check back regularly for verified press releases and objective analysis of events shaping the future of precision oncology therapeutics.
Theseus Pharmaceuticals (NASDAQ: THRX) has announced the nomination of THE-349 as a development candidate for its EGFR inhibitor program targeting non-small cell lung cancer (NSCLC). This fourth-generation small molecule aims to inhibit major activating and resistance mutations in EGFR, particularly in patients resistant to existing therapies. Preclinical data will be presented at the 34th EORTC-NCI-AACR Symposium in Barcelona from October 26-28, 2022, with an IND submission anticipated in H2 2023.
Theseus Pharmaceuticals (NASDAQ: THRX) will attend three investor conferences in September 2022, showcasing its commitment to cancer treatment.
- H.C. Wainwright Conference: September 13, 12:00 PM ET - Company Presentation
- Morgan Stanley Healthcare Conference: September 14, 3:30 PM ET - Fireside Chat
- Cantor Fitzgerald Oncology Conference: September 28, 11:30 AM ET - Panel Discussion
Webcasts are available on the investor relations website and will be archived for 30 days. Theseus focuses on targeted therapies for cancer patients, including lead candidate THE-630 for gastrointestinal tumors.
Theseus Pharmaceuticals (THRX) announced its Q2 2022 financial results, reporting a net loss of $11.6 million, up from $6.8 million in Q2 2021. Cash, cash equivalents, and investments totaled $228.6 million, projected to fund operations into Q4 2024. The company is advancing its clinical pipeline, with the Phase 1/2 trial for THE-630 on track and initial data expected in Q2 2023. Additionally, a development candidate for a fourth-generation EGFR inhibitor is anticipated in Q3 2022, with an IND submission planned for 2023.
Theseus Pharmaceuticals (NASDAQ: THRX) will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 10:20 AM ET for a panel discussion. The event will be accessible via a live webcast on the company's investor relations website, with an archived version available for 30 days. The management team will also engage in one-on-one meetings with investors during the conference. Theseus focuses on developing targeted therapies to combat cancer, including its lead candidate, THE-630, aimed at advanced gastrointestinal stromal tumors.
Theseus Pharmaceuticals (NASDAQ: THRX) announced its participation in two upcoming investor conferences. The H.C. Wainwright Global Investment Conference will take place virtually from May 23-26, 2022, featuring an on-demand presentation. Additionally, Theseus will participate in the Jefferies Healthcare Conference with a live fireside chat on June 9, 2022 at 4:30 PM ET. Investors can access a live webcast on the company's website, with archived presentations available for 30 days.
Theseus Pharmaceuticals (THRX) announced the appointment of Don Hayden to its Board of Directors on May 18, 2022. With over 40 years of experience in the life sciences sector, Hayden's expertise includes significant roles at Bristol Myers-Squibb and various biopharmaceutical companies. His addition is expected to bolster Theseus' strategic direction, particularly as it advances its Phase 1/2 clinical trial for THE-630 targeting gastrointestinal stromal tumors and plans to file an IND for a new EGFR-driven lung cancer therapy in 2023. This leadership change aims to enhance the company’s growth and clinical development efforts.
Theseus Pharmaceuticals (NASDAQ: THRX) has announced business highlights and financial results for Q1 2022. The company is actively enrolling patients in the Phase 1/2 trial for THE-630, targeting advanced gastrointestinal stromal tumors (GIST), with initial data expected in 1H 2023. As of March 31, 2022, Theseus has $237 million in cash, financing operations into late 2024. R&D expenses increased to $6.5 million, while G&A expenses rose to $4 million, resulting in a net loss of $10.5 million. Future milestones include nominating a fourth-generation EGFR candidate in Q3 2022.
Theseus Pharmaceuticals (THRX) announced preclinical data on its fourth-generation EGFR inhibitors at the AACR Annual Meeting 2022. The lead compounds demonstrated potent inhibition of major EGFR variants, including resistant mutations like T790M and C797S, with IC50 values ranging from 2-12 nM and favorable selectivity over wild-type EGFR. Additionally, these compounds showed the ability to cause tumor regressions in mice. The company plans to nominate a development candidate in Q3 2022 and expects to file an IND in 2023.
Theseus Pharmaceuticals (NASDAQ: THRX), a clinical-stage biopharmaceutical company focusing on cancer treatments, announced participation in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. The company's presentation is scheduled for April 13, 2022, at 12:45 PM ET, with a live webcast available on their investor relations website. Additionally, management will engage in one-on-one investor meetings throughout the conference. Theseus aims to combat cancer resistance through innovative therapies, including its lead candidate, THE-630, targeting advanced gastrointestinal stromal tumors.
Theseus Pharmaceuticals (NASDAQ: THRX) announced significant 2021 developments, including the initiation of a Phase 1/2 trial for lead candidate THE-630 targeting advanced GIST patients. The company added cash reserves of $244.7 million as of December 31, 2021, expected to fund operations into 2024. However, net losses increased to $8.7 million for Q4 2021 and $27.3 million for the full year, reflecting R&D and administrative expenses rising to $18.3 million and $9.0 million, respectively. Despite these losses, the company remains focused on advancing its clinical pipeline.
FAQ
What is the market cap of Theseus Pharmaceuticals (THRX)?
